37th International Papillomavirus Conference (IPVC 2025)

The 37th International Papillomavirus Conference (IPVC 2025) is dedicated to papillomaviruses and their associated diseases.

Topics

• Clinical Research
  • HPV diagnostics and biomarkers II: Validation platforms (e.g. Valgent)
  • HPV diagnostics and biomarkers I: HPV triage technologies
  • HPV self-collection
  • HPV diagnostics and biomarkers III: Quality and performance verification for clinical HPV tests
  • Diagnosis and management of anal cancer and its precursors
  • Diagnosis and management of cervical cancer and its precursors
  • Diagnosis and management of oropharyngeal, head and neck cancer
  • Diagnosis and management of penile, vulvar and vaginal cancer and precursors
  • Diagnosis and management of HPV associated skin lesions other than warts
  • Diagnosis and management of genital and skin warts
  • Therapeutic vaccines - clinical aspects
  • Prophylactic vaccines - clinical aspects
  • Treatment of precancer in low resource settings
  • Management of HPV disease in HIV-infected people
  • Treatment of HPV-related disease
  • Cochrane reviews of HPV vaccination and screening
  • Recurrent Respiratory Papillomatosis
  • Other clinical research
• Basic Research
  • Animal models
  • Taxonomy
  • Regulation of gene expression
  • Immunology
  • Structural biology
  • Transformation and carcinogenesis
  • Virus life cycle
  • Virus - host interactions
  • Papillomavirus vaccines (i.e. new developments)
  • Genomics of HPV-associated disease
  • Other basic research
• High resource settings
  • Vaccination: implementation, evaluation and impact
  • Screening for HPV related disease: implementation, evaluation and impact
  • Primary HPV vs co-testing with HPV and cytology
  • Economics and mathematical modelling in HIC
  • Screening for HPV related disease screening: implementation, evaluation and impact`
  • Low and middle income (LMIC) settings
  • Cervical screening and combined screening vaccination strategies in LMIC
  • Scale up of HPV vaccination in Gavi-eligible countries
  • Vaccine and screening implementation in non GAVI-eligible/middle income countries
  • Economics and mathematical modelling for LMIC
  • Psychosocial impact of new HPV and cervical cancer prevention strategies
  • Other public health / epidemiology research
• Public Health / Epidemiology
  • Epidemiology: natural history/global burden/risk factors
  • Global impact of HPV and cervical cancer prevention
  • Vaccine safety: new evidence and public perception
  • Screening for HPV related disease: implementation, evaluation and impact
  • Cancer control in Indigenous peoples
  • Quality standards and methods for economics and mathematical modelling (e.g. HPV-FRAME)
  • Cancer control in Culturally And Linguistically Diverse Groups (CALD)